Outcome MeasureDepression

DASS-21

Depression Anxiety Stress Scales – 21 Item

3 Papers in Blossom

Clinical Thresholds

Normal

Mild

Moderate

Severe

Extremely Severe

0126

Normal

Score 0–28

Mild

Score 29–42

Moderate

Score 43–56

Severe

Score 57–84

Extremely Severe

Score 85–126

Outcome Data Across Studies

Reported results for DASS-21 across 1 study with quantitative data.

Outcome data across 3 study arm–timepoint observations
					SD
Oral ketamine reduces the experience of stress in people with chronic suicidality 2022Secondary	Oral ketamine(experimental)	0	32	33.8	7.3	—
Oral ketamine reduces the experience of stress in people with chronic suicidality 2022Secondary	Oral ketamine(experimental)	42	32	15.7	11.9	—
Oral ketamine reduces the experience of stress in people with chronic suicidality 2022Secondary	Oral ketamine(experimental)	70	30	21.5	12.8	—

Papers Using DASS-21

Open Accessindividual

LSD microdosing in major depressive disorder: results from an open-label trial

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Published: February 1, 2026
Journal: Neuropharmacology
Authors: Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L., Forsyth, A., Evans, W. J., Alshakhouri, M., Reynolds, L. M, Roop, P., Ponton, R., Smith, T., Hoeh, N. R., Allen, N., Sundram, F., Menkes, D. B., Muthukumaraswamy, S.

Open Accessindividual

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

In a single‑arm, open‑label pilot of 15 people with methamphetamine use disorder, outpatient psilocybin‑assisted psychotherapy (single 25 mg oral dose with preparatory and integration sessions) was feasible and well tolerated with no serious adverse events, and was associated with reductions in self‑reported methamphetamine use and craving at 28 and 90 days; a larger randomised trial is required to confirm efficacy and safety.

Published: September 20, 2025
Journal: Addiction
Authors: Knock, E., Siefried, K. J., Gill Bedi, |., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., Brett, J., Bedi, G.

Paywallindividual

Oral ketamine reduces the experience of stress in people with chronic suicidality

This open-label study (n=32) investigated the efficacy of weekly oral ketamine (35-210 mg/70 kg) for reducing stress in adults with chronic suicidality. Results indicate that ketamine produced a robust and clinically significant reduction in self-reported stress, which was sustained in a subgroup of participants during the four-week follow-up.

Published: March 1, 2022
Journal: Journal of Affective Disorders
Authors: Dutton, M., Can, A. T., Beaudequin, D., Jensen, E., Jones, M., Gallay, C. C., Schwenn, P. E., Scherman, J. K., Yang, C., Forsyth, G., Lagopoulos, J., Hermens, D. F.

Quick Facts

Full Name: Depression Anxiety Stress Scales – 21 Item
Domain: Depression
Papers Indexed: 3
Score Range: 0–126
Interpretation: Lower = better

All Measures